254 results on '"Spicak, J."'
Search Results
102. The role of antibiotic treatment in severe form of acute pancreatitis: A randomized prospective study
- Author
-
Hubaczova, M., Spicak, J., Antos, F., Bartova, I., Cech, P., Kasalicky, P., Kostka, R., Lata, J., Leffler, J., and Zavoral, M.
- Published
- 2001
- Full Text
- View/download PDF
103. Celecoxib for the prevention of colorectal adenomatous polyps.
- Author
-
Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, and PreSAP (Prevention of Colorectal Sporadic Adenomatous Polyps) Trial Investigators
- Published
- 2006
104. Juxtapapillary diverticula: Relation to bile stones
- Author
-
Špičák, J., Dufek, V., and Ist, V.Chmel
- Published
- 1990
- Full Text
- View/download PDF
105. P-045 - Long-term results of endoscopic treatment vs. esophagectomy with lymphadenectomy in patients with high-risk early esophageal cancer including detailed analysis of lymph node micrometastases.
- Author
-
Kollar, M., Krajciova, J., Prefertusova, L., Sticova, E., Maluskova, J., Pazdro, A., Haruštiak, T., Spicak, J., Vackova, Z., and Martinek, J.
- Subjects
- *
ESOPHAGEAL cancer , *LYMPH nodes , *ESOPHAGECTOMY , *LYMPHADENECTOMY , *THERAPEUTICS - Published
- 2019
- Full Text
- View/download PDF
106. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis
- Author
-
Heiko, Witt, Miklos Sahin Toth, Olfert, Landt, Jian Min Chen, Thilo, Kahne, Drenth, Joost P. H., Zoltan, Kukor, Edit, Szepessy, Walter, Halangk, Stefan, Dahm, Klaus, Rohde, Hans Ulrich Schulz, Cedric Le Marechal, Nejat, Akar, Ammann, Rudolf W., Kaspar, Truninger, Mario, Bargetzi, Eesh, Bhatia, Carlo, Castellani, Giulia Martina Cavestro, Milos, Cerny, DESTRO-BISOL, Giovanni, Spedini, Gabriella, Hans, Eiberg, Jansen, Jan B. M. J., Monika, Koudova, Eva, Rausova, Milan, Macek, Macek Jr, M., Nuria, Malats, Real, Francisco X., Hans Jurgen Menzel, Pedro, Moral, Roberta, Galavotti, Pier Franco Pignatti, Olga, Rickards, Julius, Spicak, Narcis Octavian Zarnescu, Wolfgang, Bock, Gress, Thomas M., Helmut, Friess, Johann, Ockenga, Hartmut, Schmidt, Roland, Pfutzer, Matthias, Lohr, Peter, Simon, Frank Ulrich Weiss, Lerch, Markus M., Niels, Teich, Volker, Keim, Thomas, Berg, Bertram, Wiedenmann, Werner, Luck, David Alexander Groneberg, Michael, Becker, Thomas, Keil, Andreas, Kage, Jana, Bernardova, Markus, Braun, Claudia, Guldner, Juliane, Halangk, Jonas, Rosendahl, Ulrike, Witt, Matthias, Treiber, Renate, Nickel, Claude, Ferec, Witt, H, SAHIN TOTH, M, Landt, O, Chen, Jm, Kahne, T, Drenth, Jp, Kukor, Z, Szepessy, E, Halangk, W, Dahm, S, Rohde, K, Schulz, Hu, LE MARECHAL, C, Akar, N, Ammann, Rw, Truninger, K, Bargetzi, M, Bhatia, E, Castellani, C, Cavestro, GIULIA MARTINA, Cerny, M, DESTRO BISOL, G, Spedini, G, Eiberg, H, Jansen, Jb, Koudova, M, Rausova, E, MACEK M., Jr, Malats, N, Real, Fx, Menzel, Hj, Moral, P, Galavotti, R, Pignatti, Pf, Rickards, O, Spicak, J, Zarnescu, No, Bock, W, Gress, Tm, Friess, H, Ockenga, J, Schmidt, H, Pfutzer, R, Lohr, M, Simon, P, Weiss, Fu, Lerch, Mm, Teich, N, Keim, V, Berg, T, Wiedenmann, B, Luck, W, Groneberg, Da, Becker, M, Keil, T, Kage, A, Bernardova, J, Braun, M, Guldner, C, Halangk, J, Rosendahl, J, Witt, U, Treiber, M, Nickel, R, and Ferec, C.
- Subjects
trypsin inhibitor ,Models, Molecular ,Enteropeptidase ,Pancreatic disease ,Membrane transport and intracellular motility [NCMLS 5] ,arginine ,genetic risk ,chemistry.chemical_compound ,Models ,proteinosis ,Trypsin ,Pancreatic Secretory Trypsin Inhibitor ,PRSS1 gene ,enteropeptidase ,medicine.diagnostic_test ,adult ,Hydrolysis ,cationic trypsinogen ,protection ,unclassified drug ,enzyme activity ,female ,priority journal ,risk factor ,CHRONIC PANCREATITIS ,protein degradation ,Trypsinogen ,medicine.drug ,medicine.medical_specialty ,anionic trypsinogen ,Proteolysis ,Biology ,Article ,male ,Internal medicine ,Genetics ,medicine ,Matrix-Assisted Laser Desorption-Ionization ,Humans ,PRSS2 ,controlled study ,human ,Molecular gastro-enterology and hepatology [IGMD 2] ,gene ,DNA Primers ,Genetic polymorphism ,catalysis ,Base Sequence ,Spectrometry ,disease predisposition ,Molecular ,cationic trypsinogen prss1 ,glycine ,pancreatic secretory trypsin inhibitor spink1 ,trypsin ,trypsinogen ,article ,chronic pancreatitis ,codon ,genetic susceptibility ,major clinical study ,nucleotide sequence ,Chronic Disease ,Haplotypes ,Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ,Mass ,medicine.disease ,Tripsinogen ,Tripsina ,Settore BIO/18 - Genetica ,Endocrinology ,Genetic defects of metabolism [UMCN 5.1] ,Pancreatitis ,chemistry ,Genètica - Abstract
Chronic pancreatitis is a common inflammatory disease of the pancreas. Mutations in the genes encoding cationic trypsinogen (PRSS1) and the pancreatic secretory trypsin inhibitor (SPINK1) are associated with chronic pancreatitis. Because increased proteolytic activity owing to mutated PRSS1 enhances the risk for chronic pancreatitis, mutations in the gene encoding anionic trypsinogen (PRSS2) may also predispose to disease. Here we analyzed PRSS2 in individuals with chronic pancreatitis and controls and found, to our surprise, that a variant of codon 191 (G191R) is overrepresented in control subjects: G191R was present in 220/6,459 (3.4%) controls but in only 32/2,466 (1.3%) affected individuals (odds ratio 0.37; P = 1.1 x 10(-8)). Upon activation by enterokinase or trypsin, purified recombinant G191R protein showed a complete loss of trypsin activity owing to the introduction of a new tryptic cleavage site that renders the enzyme hypersensitive to autocatalytic proteolysis. In conclusion, the G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis. The initial experiments were supported by the DFG (Wi 2036/1-1). This work was supported by the Sonnenfeld-Stiftung, Berlin, Germany (to H.W.), the US National Institutes of Health (NIH) (grant DK058088 to M.S.-T.), INSERM (Institut National de la Santé et de la Recherche Médicale) and the Programme Hospitalier de Recherche Clinique (grant PHRC R 08-04 to C.F.)
- Published
- 2006
107. Long-term Results of Duodeno-jejunal Bypass in the Treatment of Obesity and Type 2 Diabetes.
- Author
-
Kral J, Benes M, Lanska V, Macinga P, Drastich P, Spicak J, and Hucl T
- Subjects
- Humans, Glycated Hemoglobin, Retrospective Studies, Treatment Outcome, Obesity surgery, Obesity complications, Duodenum surgery, Jejunum surgery, Weight Loss, Diabetes Mellitus, Type 2 surgery, Diabetes Mellitus, Type 2 complications, Obesity, Morbid surgery, Gastric Bypass methods
- Abstract
Purpose: Obesity and its related severe comorbidities are increasing rapidly. The duodenal-jejunal bypass is an endoscopically implanted device (mimicking the Roux-en-Y gastric bypass) developed to support weight reduction and improve type 2 diabetes control., Materials and Methods: Retrospective data analysis of consecutive patients undergoing duodenal-jejunal bypass (EndoBarrier®, DJB) implantation between 2013 and 2017 was performed to evaluate safety as well as short- and long-term efficacy., Results: One hundred and twenty-one patients (mean BMI of 43.1 ± 7.2 kg/m
2 and weight of 138.2 ± 28.6 kg) underwent DJB implantation. The mean dwelling time was 15.5 months, the mean total body weight loss (%TBWL) after explantation was 10.3% ± 7.9% (14.2 kg, p < 0.0001), and the mean BMI was 39.5 ± 7.3 kg/m2 (p < 0.0001). There was no significant weight gain 24 months after the explantation. Seventy-seven patients had type 2 diabetes mellitus (T2DM) with a mean HbA1c before implantation of 5.6% (n = 52). The mean HbA1c after explantation was 5.1% (p = 0.0001). Significant reductions in transaminase and lipid levels before and after explantation were observed. One complication occurred during implantation and another during explantation. In 16 patients, the device had to be extracted earlier than expected (7 for severe adverse events and 9 for adverse events; 13.2%)., Conclusion: Despite an evident rate of adverse events, the DJB shows promise as a weight-loss procedure. Our results show that some patients implanted with the device maintained reduced weight even 24 months after explantation, while many improved T2DM control., (© 2023. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
108. Cutting-edge novel device in the treatment of obesity.
- Author
-
Kral J, Selucka J, Waloszkova K, Buzga M, Spicak J, and Machytka E
- Subjects
- Humans, Obesity surgery
- Abstract
Competing Interests: First in Human Study was supported by Nitinotes company which developed this device.
- Published
- 2024
- Full Text
- View/download PDF
109. Correction: Cutting-edge novel device in the treatment of obesity.
- Author
-
Kral J, Selucka J, Waloszkova K, Buzga M, Spicak J, and Machytka E
- Abstract
Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2024
- Full Text
- View/download PDF
110. Correction: Cutting-edge novel device in the treatment of obesity.
- Author
-
Kral J, Selucka J, Waloszkova K, Buzga M, Spicak J, and Machytka E
- Abstract
Competing Interests: Disclosure The authors report no conflicts of interest in this work.
- Published
- 2023
- Full Text
- View/download PDF
111. Endoscopic management of gastrojejunocolic fistula as an unusual complication of endoscopic ultrasound-guided gastroenterostomy.
- Author
-
Hujova A, Stirand P, Turza P, Spicak J, and Hucl T
- Subjects
- Humans, Gastroenterostomy adverse effects, Ultrasonography, Interventional adverse effects, Endosonography adverse effects, Intestinal Fistula surgery, Intestinal Fistula complications, Gastric Fistula etiology, Gastric Fistula surgery, Colonic Diseases etiology, Colonic Diseases surgery
- Abstract
Competing Interests: The authors declare that they have no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
112. Cutting-edge novel device in the treatment of obesity.
- Author
-
Kral J, Selucka J, Waloszkova K, Buzga M, Spicak J, and Machytka E
- Subjects
- Humans, Equipment Design, Obesity surgery
- Abstract
Competing Interests: First in Human Study was supported by Nitinotes company which developed this device.
- Published
- 2023
- Full Text
- View/download PDF
113. Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial.
- Author
-
Jarosova J, Zarivnijova L, Cibulkova I, Mares J, Macinga P, Hujova A, Falt P, Urban O, Hajer J, Spicak J, and Hucl T
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Aged, 80 and over, Quality of Life, Stents adverse effects, Bile Ducts, Intrahepatic surgery, Treatment Outcome, Catheter Ablation adverse effects, Catheter Ablation methods, Radiofrequency Ablation, Cholangiocarcinoma, Pancreatic Neoplasms complications, Pancreatic Neoplasms surgery, Cholestasis etiology, Cholestasis surgery, Bile Duct Neoplasms complications, Bile Duct Neoplasms surgery
- Abstract
Background: Endoluminal radiofrequency ablation (RFA) has been promoted as palliative treatment for patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) in order to improve biliary drainage and eventually prolong survival. No high level evidence is, however, available on this technique., Design: In this randomised controlled study, we compared endoluminal RFA plus stenting with stenting alone (control group) in patients with malignant biliary obstruction; metal stents were primarily placed. Primary outcome was overall survival; secondary outcomes were stent patency, quality of life and adverse events. In a superiority design, survival was assumed to be doubled by RFA as compared with 6.4 months in the control group (n=280)., Results: A total of 161 patients (male:female 90:71, mean age 71±9 years) were randomised before recruitment was terminated for futility after an interim analysis. Eighty-five patients had CCA (73 hilar, 12 distal) and 76 had pancreatic cancer. There was no difference in survival in both subgroups: for patients with CCA, median survival was 10.5 months (95% CI 6.7 to 18.3) in the RFA group vs 10.6 months (95% CI 9.0 to 24.8), p=0.58)) in the control group. In the subgroup with pancreatic cancer, median survival was 6.4 months (95% CI 4.3 to 9.7) for the RFA vs 7.7 months (95% CI 5.6 to 11.3), p=0.73) for the control group. No benefit was seen in the RFA group with regard to stent patency (at 12 months 40% vs 36% in CCA and 66% vs 65% in PDAC), and quality of life was unchanged by either treatment and comparable between the groups. Adverse events occurred in seven patients in each groups., Conclusion: A combination of endoluminal RFA and stenting was not superior to stenting alone in prolonging survival or improving stent patency in patients with malignant biliary obstruction., Trial Registration Number: NCT03166436., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
114. Periprocedural safety profile of peroral endoscopic myotomy (POEM)-a retrospective analysis of adverse events according to two different classifications.
- Author
-
Simkova D, Mares J, Vackova Z, Hucl T, Stirand P, Kieslichova E, Ryska O, Spicak J, Drazilova S, Veseliny E, and Martinek J
- Subjects
- Humans, Retrospective Studies, Risk Factors, Treatment Outcome, Esophageal Sphincter, Lower surgery, Esophageal Achalasia surgery, Digestive System Surgical Procedures, Myotomy methods, Natural Orifice Endoscopic Surgery methods
- Abstract
Background: Peroral endoscopic myotomy (POEM) is nowadays a standard method for treatment of achalasia; nevertheless, it remains an invasive intervention with corresponding risk of adverse events (AEs). The classification and grading of AEs are still a matter of discussion. The aim of our retrospective study was to assess the occurrence of all "undesirable" events and "true" adverse events in patients undergoing POEM and to compare the outcomes when either Clavien-Dindo classification (CDC) or American Society of Gastrointestinal Endoscopy (ASGE) lexicon classification applied., Methods: This was a retrospective analysis of prospectively managed database of all patients who had undergone POEM between December 2012 and August 2018. We assessed the pre-, peri-, and early-postoperative (up to patient's discharge) undesirable events (including those not fulfilling criteria for AEs) and "true" AEs according the definition in either of the classifications., Results: A total of 231 patients have successfully undergone 244 POEM procedures (13 × re-POEM). Twenty-nine procedures (11.9%) passed uneventfully, while in 215 procedures (88.1%), a total of 440 undesirable events occurred. The CDC identified 27 AEs (17 minor, 10 major) occurring in 23/244 (9.4%) procedures. The ASGE lexicon identified identical 27 AEs (21 mild or moderate, 6 severe or fatal) resulting in the severity distribution of AEs being the only difference between the two classifications. Only the absence of previous treatment was found to be a risk factor [p = 0.047, OR with 95% CI: 4.55 (1.02; 20.25)] in the combined logistic regression model., Conclusion: Undesirable events are common in patients undergoing POEM but the incidence of true AEs is low according to both classifications. Severe adverse events are infrequent irrespective of the classification applied. CDC may be more appropriate than ASGE lexicon for classifying POEM-related AEs given a surgical nature of this procedure., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
115. Acute Pancreatitis in Patients After Liver Transplantation.
- Author
-
Hujova A, Macinga P, Jarosova J, Fronek J, Taimr P, Spicak J, and Hucl T
- Subjects
- Humans, Acute Disease, Risk Factors, Incidence, Pancreatitis etiology, Pancreatitis diagnosis, Liver Transplantation adverse effects
- Abstract
BACKGROUND Acute pancreatitis (AP) is a relatively rare but serious complication that can occur after organ transplantation. MATERIAL AND METHODS The aim of this study was to evaluate the incidence, potential risk factors, and course of AP in patients following liver transplantation at a single large-volume transplant center. RESULTS Out of a total of 1850 transplanted patients, 49 (2.8%) were diagnosed with AP. Of this group, 37 (75.5%) had a mild form of AP and 12 (24.5%) had a severe form of AP. The mortality rate was 10% overall and 42% in the group of patients with severe AP. An early form of AP (<30 days from transplantation) occurred in 13 patients (26.5%), most of whom presented with severe AP (10 patients, 76.9%); 4 patients died (40%). A late form of AP was diagnosed in 36 patients (73.5%), most of whom had mild AP (34 patients, 94.4%); 1 of 2 patients with severe AP died. The most common AP etiologies were post-ERCP (38.8%), idiopathic (34.7%), and postoperative (18.4%). Chronic HBV infection was a risk factor for development of AP (P=0.01). CONCLUSIONS AP in liver transplant recipients was more frequent and more severe than in the general population. This unfavorable course was associated with the occurrence of AP in the early post-transplant period. Liver transplantation due to complications of HBV infection was a risk factor for the development of AP.
- Published
- 2022
- Full Text
- View/download PDF
116. Endoscopic extraction of migrated gastric bypass Fobi ring in patient after gastric bypass.
- Author
-
Kral J, Selucka J, Dolecek F, Waloszkova K, Buzga M, Spicak J, and Machytka E
- Subjects
- Humans, Anastomosis, Roux-en-Y, Endoscopy, Gastric Bypass adverse effects, Obesity, Morbid surgery
- Abstract
Competing Interests: The authors declare that they have no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
117. Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial.
- Author
-
Martinek J, Hustak R, Mares J, Vackova Z, Spicak J, Kieslichova E, Buncova M, Pohl D, Amin S, and Tack J
- Subjects
- Female, Gastric Emptying, Gastroscopy methods, Humans, Male, Prospective Studies, Treatment Outcome, Gastroparesis etiology, Gastroparesis surgery, Pyloromyotomy adverse effects, Pyloromyotomy methods
- Abstract
Objective: Endoscopic pyloromyotomy (G-POEM) is a minimally invasive treatment option with promising uncontrolled outcome results in patients with gastroparesis., Design: In this prospective randomised trial, we compared G-POEM with a sham procedure in patients with severe gastroparesis. The primary outcome was the proportion of patients with treatment success (defined as a decrease in the Gastroparesis Cardinal Symptom Index (GCSI) by at least 50%) at 6 months. Patients randomised to the sham group with persistent symptoms were offered cross-over G-POEM., Results: The enrolment was stopped after the interim analysis by the Data and Safety Monitoring Board prior to reaching the planned sample of 86 patients. A total of 41 patients (17 diabetic, 13 postsurgical, 11 idiopathic; 46% male) were randomised (21 G-POEM, 20-sham). Treatment success rate was 71% (95% CI 50 to 86) after G-POEM versus 22% (8-47) after sham (p=0.005). Treatment success in patients with diabetic, postsurgical and idiopathic gastroparesis was 89% (95% CI 56 to 98), 50% (18-82) and 67% (30-90) after G-POEM; the corresponding rates in the sham group were 17% (3-57), 29% (7-67) and 20% (3-67).Median gastric retention at 4 hours decreased from 22% (95% CI 17 to 31) to 12% (5-22) after G-POEM and did not change after sham: 26% (18-39) versus 24% (11-35). Twelve patients crossed over to G-POEM with 9 of them (75%) achieving treatment success., Conclusion: In severe gastroparesis, G-POEM is superior to a sham procedure for improving both symptoms and gastric emptying 6 months after the procedure. These results are not entirely conclusive in patients with idiopathic and postsurgical aetiologies., Trial Registration Number: NCT03356067; ClinicalTrials.gov., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
118. Impact of Endoluminal Radiofrequency Ablation on Immunity in Pancreatic Cancer and Cholangiocarcinoma.
- Author
-
Jarosova J, Macinga P, Krupickova L, Fialova M, Hujova A, Mares J, Urban O, Hajer J, Spicak J, Striz I, and Hucl T
- Abstract
Radiofrequency ablation (RFA) is a mini-invasive loco-regional ablation technique that is increasingly being used as a palliative treatment for pancreatic cancer and cholangiocarcinoma. Ablation-triggered immune system stimulation has been proposed as a mechanism behind the systemic effects of RFA. The aim of our study was to investigate the immune response to endoluminal biliary RFA. Peripheral blood samples were collected from patients with pancreatic cancer and cholangiocarcinoma randomised to receive endoluminal biliary radiofrequency ablation + stent (19 patients) or stent only (21 patients). We observed an early increase in IL-6 levels and a delayed increase in CXCL1, CXCL5, and CXCL11 levels as well as an increase in CD8+ and NK cells. However, these changes were not specific to RFA treatment. Explicitly in response to RFA, we observed a delayed increase in serum CXCL1 levels and an early decrease in the number of anti-inflammatory CD206+ blood monocytes. Our study provides the first evidence of endoluminal biliary RFA-based regulation of the systemic immune response in patients with pancreatic cancer and cholangiocarcinoma. These changes were characterised by a general inflammatory response. RFA-specific activation of the adaptive immune system was not confirmed.
- Published
- 2022
- Full Text
- View/download PDF
119. Biliary obstruction following transjugular intrahepatic portosystemic shunt placement in a patient after liver transplantation: A case report.
- Author
-
Macinga P, Gogova D, Raupach J, Jarosova J, Janousek L, Honsova E, Taimr P, Spicak J, Novotny J, Peregrin J, and Hucl T
- Abstract
Background: Transjugular intrahepatic portosystemic shunt (TIPS) is a method used to decrease portal hypertension. Biliary stricture is the rarest of the complications associated with this procedure with only 12 cases previously reported in the literature. None of these cases have documented the resolution of biliary stenosis induced by a stent graft. The only curative solutions reported are liver transplantation or bypassing the stenosis with an artificial biliary tract using advanced endoscopic techniques., Case Summary: This is the first reported case of biliary obstruction secondary to TIPS placement in a transplanted liver. In our patient, a portosystemic shunt was created to treat severe veno-occlusive liver graft disease manifesting itself primarily by fluid retention. A cholestatic liver lesion and cholangitis with abscesses developed due to a stent graft-induced stricture in the dorsal segment of the right hepatic duct and the stricture diminished following percutaneous drainage. Endoscopic drainage was performed after unsuccessful removal of the percutaneous catheter resulting in a bilio-cutaneous fistula. Although the liver graft now functions well, the stricture remains refractory even after 44 mo of treatment., Conclusion: Biliary strictures caused by TIPS in both transplanted and native livers seem refractory to endoscopic treatment., Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
120. Peristaltic Recovery After Peroral Endoscopic Myotomy for Achalasia: Dream or Reality?: Author's Reply.
- Author
-
Vackova Z, Mares J, Krajciova J, Rabekova Z, Zdrhova L, Loudova P, Spicak J, Stirand P, Hucl T, and Martinek J
- Published
- 2022
- Full Text
- View/download PDF
121. Endoscopic radiofrequency ablation for malignant biliary obstruction.
- Author
-
Jarosova J, Macinga P, Hujova A, Kral J, Urban O, Spicak J, and Hucl T
- Abstract
Cholangiocarcinoma and pancreatic cancer are the most common causes of malignant biliary obstruction. The majority of patients are diagnosed at a late stage when surgical resection is rarely possible. In these cases, palliative chemotherapy and radiotherapy provide only limited benefit and are associated with poor survival. Radiofrequency ablation (RFA) is a procedure for locoregional control of tumours, whereby a high-frequency alternating current turned into thermal energy causes coagulative necrosis of the tissue surrounding the catheter. The subsequent release of debris and tumour antigens by necrotic cells can stimulate local and systemic immunity. The development of endoluminal RFA catheters has led to the emergence of endoscopically delivered RFA, a treatment mainly used for malignant biliary strictures to prolong survival and/or stent patency. Other indications include recanalisation of occluded biliary stents and treatment of intraductal ampullary adenoma or benign biliary strictures. This article presents a comprehensive review of endobiliary RFA, mainly focusing on its use in patients with malignant biliary obstruction. The available data suggest that biliary RFA may be a promising modality, having positive impacts on survival and stent patency and boasting a reasonable safety profile. However, further studies with better characterised and stratified patient populations are needed before the method becomes accepted within routine clinical practice., Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
122. Alpha-1 Antitrypsin and Hepatocellular Carcinoma in Liver Cirrhosis: SERPINA1 MZ or MS Genotype Carriage Decreases the Risk.
- Author
-
Rabekova Z, Frankova S, Jirsa M, Neroldova M, Lunova M, Fabian O, Kveton M, Varys D, Chmelova K, Adamkova V, Hubacek JA, Spicak J, Merta D, and Sperl J
- Subjects
- Alleles, Body Mass Index, Carcinoma, Hepatocellular complications, Female, Gene Frequency, Genotype, Humans, Liver Cirrhosis complications, Liver Neoplasms complications, Male, Middle Aged, Multivariate Analysis, Risk Factors, Sex Factors, alpha 1-Antitrypsin blood, Carcinoma, Hepatocellular genetics, Liver Cirrhosis genetics, Liver Neoplasms genetics, alpha 1-Antitrypsin genetics
- Abstract
Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups consisted of 1119 patients with liver cirrhosis of various aetiologies, and 3240 healthy individuals served as population controls. The MZ genotype was significantly more frequent in the study group (55/1119 vs. 87/3240, p < 0.0001). The MS genotype frequency was comparable in controls (32/119 vs. 101/3240, p = 0.84). MZ and MS heterozygotes had lower serum AAT level than MM homozygotes (medians: 0.90 g/L; 1.40 g/L and 1.67 g/L; p < 0.001 for both). There were significantly fewer patients with HCC in the cirrhosis group among MZ and MS heterozygotes than in MM homozygotes (5/55 and 1/32 respectively, vs. 243/1022, p < 0.01 for both). The risk of HCC was lower in MZ and MS heterozygotes than in MM homozygotes (OR 0.3202; 95% CI 0.1361-0.7719 and OR 0.1522; 95% CI 0.02941-0.7882, respectively). Multivariate analysis of HCC risk factors identified MZ or MS genotype carriage as a protective factor, whereas age, male sex, BMI and viral aetiology of cirrhosis increased HCC risk.
- Published
- 2021
- Full Text
- View/download PDF
123. Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis.
- Author
-
Lunova M, Frankova S, Gottfriedova H, Senkerikova R, Neroldova M, Kovac J, Kieslichova E, Lanska V, Sticova E, Spicak J, Jirsa M, and Sperl J
- Subjects
- Adult, Aged, Collagen analysis, Elasticity Imaging Techniques, Female, Humans, Hypertension, Portal diagnosis, Hypertension, Portal surgery, Liver chemistry, Liver diagnostic imaging, Liver surgery, Liver Cirrhosis metabolism, Liver Cirrhosis physiopathology, Liver Cirrhosis surgery, Liver Transplantation, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Young Adult, Hypertension, Portal physiopathology, Liver pathology, Liver Cirrhosis pathology, Portal Pressure
- Abstract
Liver stiffness (LS) is a novel non-invasive parameter widely used in clinical hepatology. LS correlates with liver fibrosis stage in non-cirrhotic patients. In cirrhotic patients it also shows good correlation with Hepatic Venous Pressure Gradient (HVPG). Our aim was to assess the contribution of liver fibrosis and portal hypertension to LS in patients with advanced liver cirrhosis. Eighty-one liver transplant candidates with liver cirrhosis of various aetiologies underwent direct HVPG and LS measurement by 2D shear-wave elastography (Aixplorer Multiwave, Supersonic Imagine, France). Liver collagen content was assessed in the explanted liver as collagen proportionate area (CPA) and hydroxyproline content (HP). The studied cohort included predominantly patients with Child-Pugh class B and C (63/81, 77.8%), minority of patients were Child-Pugh A (18/81, 22.2%). LS showed the best correlation with HVPG (r=0.719, p< 0.001), correlation of LS with CPA (r=0.441, p< 0.001) and HP/Amino Acids (r=0.414, p< 0.001) was weaker. Both variables expressing liver collagen content showed good correlation with each other (r=0.574, p<0.001). Multiple linear regression identified the strongest association between LS and HVPG (p < 0.0001) and weaker association of LS with CPA (p = 0.01883). Stepwise modelling showed minimal increase in r2 after addition of CPA to HVPG (0.5073 vs. 0.5513). The derived formula expressing LS value formation is: LS = 2.48 + (1.29 x HVPG) + (0.26 x CPA). We conclude that LS is determined predominantly by HVPG in patients with advanced liver cirrhosis whereas contribution of liver collagen content is relatively low.
- Published
- 2021
- Full Text
- View/download PDF
124. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review.
- Author
-
Macinga P, Bajer L, Del Chiaro M, Chari ST, Dite P, Frulloni L, Ikeura T, Kamisawa T, Kubota K, Naitoh I, Okazaki K, Pezzilli R, Vujasinovic M, Spicak J, Hucl T, and Lӧhr M
- Subjects
- Diagnosis, Differential, Humans, Pancreatic Neoplasms, Autoimmune Diseases complications, Autoimmune Diseases diagnosis, Autoimmune Diseases epidemiology, Autoimmune Pancreatitis, Pancreatic Neoplasms complications, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology
- Abstract
Background: Chronic pancreatitis is a known risk factor of pancreatic cancer (PDAC). A similar association has been suggested but not demonstrated for autoimmune pancreatitis (AIP)., Objective: The aim of our study was to identify and analyse all published cases of AIP and PDAC co-occurrence, focusing on the interval between the diagnoses and the cancer site within the pancreas., Methods: Relevant studies were identified through automatic searches of the MEDLINE, EMBASE, Scopus, and Web of Science databases, and supplemented by manual checks of reference lists in all retrieved articles. Missing/unpublished data were obtained from the authors of relevant publications in the form of pre-prepared questionnaires., Results: A total of 45 cases of PDAC in AIP patients were identified, of which 12 were excluded from the analysis due to suspicions of duplicity or lack of sufficient data. Thirty-one patients (94%) had type 1 AIP. Synchronous occurrence of PDAC and AIP was reported in 11 patients (33%), metachronous in 22 patients (67%). In the metachronous group, the median period between diagnoses was 66.5 months (2-186) and a majority of cancers (86%) occurred more than two years after AIP diagnosis. In most patients (70%), the cancer originated in the part of the pancreas affected by AIP., Conclusions: In the literature, there are reports on numerous cases of PDAC in AIP patients. PDAC is more frequent in AIP type 1 patients, typically metachronous in character, and generally found in the part of the pancreas affected by AIP., (Copyright © 2021 IAP and EPC. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
125. Esophageal Motility Patterns After Peroral Endoscopic Myotomy in Patients With Achalasia.
- Author
-
Vackova Z, Mares J, Krajciova J, Rabekova Z, Zdrhova L, Loudova P, Spicak J, Stirand P, Hucl T, and Martinek J
- Abstract
Background/aims: Several studies have reported partial recovery of peristalsis in patients with achalasia after myotomy. The aim of our study is to analyze esophageal motility patterns after peroral endoscopic myotomy (POEM) and to assess the potential predictors and clinical impact of peristaltic recovery., Methods: We performed a retrospective analysis of prospectively collected data of consecutive patients with achalasia undergoing POEM at a tertiary center. High-resolution manometry (HRM) studies prior to and after POEM were reviewed and the Chicago classification was applied., Results: A total of 237 patients were analyzed. The initial HRM diagnoses were achalasia type I, 42 (17.7%); type II, 173 (73.0%); and type III, 22 (9.3%). Before POEM, peristaltic fragments were present in 23 (9.7%) patients. After POEM the Chicago classification diagnoses were: 112 absent contractility, 42 type I achalasia, 15 type II, 11 type III, 26 ineffective esophageal motility, 18 esophagogastric junction outflow obstruction, 10 fragmented peristalsis, and 3 distal esophageal spasm. Altogether 68 patients (28.7%) had signs of contractile activity, but the contractions newly appeared in 47 patients (47/214, 22.0%). Type II achalasia showed a trend for appearance of contractions ( P = 0.097). Logistic regression analysis did not identify any predictors of peristaltic recovery. The post-POEM Eckardt score did not differ between patients with and without contractions nor did the parameters of timed barium esophagogram., Conclusions: More than 20% of achalasia patients have signs of partial recovery of esophageal peristalsis after POEM. It occurs predominantly in type II achalasia but the clinical relevance seems to be negligible.
- Published
- 2021
- Full Text
- View/download PDF
126. Liver stiffness measured by two-dimensional shear-wave elastography predicts hepatic vein pressure gradient at high values in liver transplant candidates with advanced liver cirrhosis.
- Author
-
Frankova S, Lunova M, Gottfriedova H, Senkerikova R, Neroldova M, Kovac J, Kieslichova E, Lanska V, Urbanek P, Spicak J, Jirsa M, and Sperl J
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers blood, Czech Republic, Female, Fibrosis pathology, Hepatic Veins pathology, Humans, Hypertension, Portal pathology, Linear Models, Liver Cirrhosis pathology, Male, Middle Aged, Portal Pressure physiology, Prospective Studies, Sensitivity and Specificity, Venous Pressure physiology, Elasticity physiology, Elasticity Imaging Techniques methods, Liver pathology
- Abstract
Liver stiffness is a reliable non-invasive predictor of Hepatic Venous Pressure Gradient (HVPG) above 10 mm Hg. However, it failed to predict higher thresholds of HVPG. Our aim was to investigate whether liver stiffness and selected previously published non-invasive blood biomarkers could predict higher HVPG thresholds in liver transplant candidates without ongoing alcohol use. One hundred and nine liver transplant candidates with liver cirrhosis of various aetiologies underwent direct HVPG measurement, liver stiffness measurement by 2D shear-wave elastography (Aixplorer Multiwave, Supersonic Imagine, France) and assessment of blood HVPG biomarkers (osteopontin, VCAM-1, IL-6, TNF-α, IL-1ra/IL-1F3 and ELF score). The correlation between liver stiffness and HVPG was linear up to 30 mm Hg of HVPG (r = 0.765, p < 0.0001). The regression lines had similar slopes for HVPG values below and above 16 mm Hg (p > 0.05) and the correlation in patients with HVPG <16 mm Hg (r = 0.456, p = 0.01) was similar to patients with HVPG ≥ 16 mm Hg (r = 0.499, p < 0.0001). The correlation was similar in the subgroup patients with alcoholic (r = 0.718, p < 0.0001), NASH (r = 0.740, p = 0.008), cryptogenic (r = 0.648, p = 0,0377), cholestatic and autoimmune (r = 0.706, p < 0.0001) and viral cirrhosis (r = 0.756, p < 0.0001). Liver stiffness distinguished patients with HVPG above 16, and 20 mm Hg with AUROCs 0.90243, and 0.86824, sensitivity 0.7656, and 0.7027, and specificity 0.9333, and 0.8750. All studied blood biomarkers correlated better with liver stiffness than with HVPG and their AUROCs did not exceed 0.8 at both HVPG thresholds. Therefore, a composite predictor superior to liver stiffness could not be established. We conclude that liver stiffness is a clinically reliable predictor of higher HVPG thresholds in non-drinking subjects with advanced liver cirrhosis., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
127. Per-oral endoscopic pyloromyotomy (g-poem) for the treatment of gastroparesis - a pilot single-centre study with mid-term follow-up.
- Author
-
Husťak R, Vacková Z, Krajciova J, Janicko M, Buncová M, Kieslichová E, Spicak J, and Martínek J
- Subjects
- Female, Follow-Up Studies, Gastric Emptying, Humans, Middle Aged, Quality of Life, Treatment Outcome, Gastroparesis surgery, Pyloromyotomy
- Abstract
Introduction: Endoscopic pyloromyotomy (G-POEM) is an emerging therapeutic method for the treatment of gastroparesis (GP). So far, only limited case-series suggesting its effectivity have been published. The aim of our study was to assess the effectivity of G-POEM in patients with refractory GP., Methods: Consecutive patients with severe and refractory GP were offered the procedure. An abnormal gastric emptying study (GES) was necessary for inclusion. The main outcome was treatment success defined as a decrease of the total GSCI symptom score by at least 40% from baseline at 3, 6, 12 and 24 months., Results: G-POEM was performed in 9 patients (5 women, mean age 56.3): 5 post-surgical, 2 diabetic, 1 idiopathic and 1 combined post-surgical and diabetic. The median follow-up was 23M (range 12-31). All procedures were successfully completed. One patient experienced delayed bleeding from gastric ulceration, which was successfully treated endoscopically; all remaining patients recovered uneventfully. Treatment success was achieved in 8/9 patients (88.9%) at 3, 6 and 12M and in 3/4 (75%) at 24M. The mean GSCI decreased from 3.16 to 0.86 (p=0.008), 0.74 (p=0.008), 1.07 (p=0.008) and 1.31 (p=0.11) at 3, 6, 12 and 24M after the procedure. The Quality of Life Index improved from the baseline value of 77 (range 48102) to 113 (86-138, p=0.03) and 96 (50-124, p=0.4) at 12 and 24M. In patients with treatment success, no recurrences have occurred so far. GES improved/normalized in all the patients., Conclusion: G-POEM was effective in 88.9% of patients with refractory GP and the effect seems to be long-lasting.
- Published
- 2020
- Full Text
- View/download PDF
128. Cardiac arrest as a fatal periprocedural complication of peroral endoscopic myotomy (POEM).
- Author
-
Hucl T, Uchytilova E, Markvartova J, Tomasek P, Kieslichova E, Spicak J, and Martinek J
- Subjects
- Humans, Treatment Outcome, Digestive System Surgical Procedures, Esophageal Achalasia surgery, Heart Arrest etiology, Myotomy adverse effects, Natural Orifice Endoscopic Surgery
- Abstract
Competing Interests: The authors declare that they have no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
129. Confocal Laser Endomicroscopy vs Biopsies in the Assessment of Persistent or Recurrent Intestinal Metaplasia/Neoplasia after Endoscopic Treatment of Barrett's Esophagus related Neoplasia.
- Author
-
Krajciova J, Kollar M, Maluskova J, Janicko M, Vackova Z, Spicak J, and Martinek J
- Subjects
- Adult, Aged, Aged, 80 and over, Barrett Esophagus pathology, Biopsy, Esophageal Neoplasms pathology, Female, Humans, Male, Middle Aged, Neoplasm Grading, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Time Factors, Treatment Outcome, Barrett Esophagus surgery, Esophageal Neoplasms surgery, Esophagectomy adverse effects, Esophagoscopy adverse effects, Microscopy, Confocal, Neoplasm Recurrence, Local, Radiofrequency Ablation
- Abstract
Background and Aims: Patients after endoscopic treatment of Barrett's esophagus (BE) related neoplasia (BORN) should enter endoscopic surveillance with biopsies to detect persistent or recurrent neoplasia or intestinal metaplasia (IM). Probe-based confocal laser endomicroscopy (pCLE) serves as a virtual biopsy and could replace standard biopsies. However, the role of pCLE in patients after endoscopic treatment of BORN has not been systematically assessed. The aim of this study was to compare pCLE with biopsies in detecting persistent/recurrent IM/neoplasia., Methods: A single center, prospective and pathologist-blinded study was performed. Patients after endoscopic treatment of BORN (endoscopic resection or dissection, radiofrequency ablation) underwent surveillance endoscopy with pCLE followed by biopsies., Results: A total of 56 patients were enrolled: initial diagnoses were low-grade dysplasia (LGD) in 24 patients (43%), high-grade dysplasia (HGD) in 12 patients (21%) and early adenocarcinoma (EAC) in 20 patients (36%). Only one patient (2%) experienced recurrent neoplasia (LGD), which was diagnosed by pCLE only. Twenty patients (35.7%) experienced persistent/recurrent IM, diagnosed by both pCLE and biopsies in 17 patients (17/30, 85%) and by pCLE only in 3 pts (3/30, 15%). Sensitivity, specificity, positive and negative predictive values to diagnose recurrent/persistent IM did not differ significantly between pCLE and biopsies; diagnostic accuracy was 100% (95%CI 93.6-100) for pCLE and 94.6 (95%CI 85.1-98.9%) for biopsies, p=0.25. In patients with IM detected by both tested methods, pCLE detected significantly more goblet cells (median 43 per patient) than biopsies (median 12 per patient), p=0.01., Conclusion: pCLE is at least as effective as standard biopsies in the detection of persistent/recurrent IM after endoscopic treatment of BORN.
- Published
- 2020
- Full Text
- View/download PDF
130. Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation.
- Author
-
Erhartova D, Cahova M, Dankova H, Heczkova M, Mikova I, Sticova E, Spicak J, Seda O, and Trunecka P
- Subjects
- Adult, Aged, Biomarkers, Biopsy, Circulating MicroRNA, Female, Humans, Male, MicroRNAs blood, Middle Aged, Non-alcoholic Fatty Liver Disease blood, Non-alcoholic Fatty Liver Disease pathology, ROC Curve, Liver Transplantation adverse effects, MicroRNAs genetics, Non-alcoholic Fatty Liver Disease etiology, Non-alcoholic Fatty Liver Disease metabolism
- Abstract
Background & Aims: MiR-33a has emerged as a critical regulator of lipid homeostasis in the liver. Genetic deficiency of miR-33a aggravates liver steatosis in a preclinical model of non-alcoholic fatty liver disease (NAFLD), and relative expression of miR-33a is increased in the livers of patients with non-alcoholic steatohepatitis (NASH). It was unknown whether miR-33a is detectable in the serum of patients with NAFLD. We sought to determine whether circulating miR-33a is associated with histological hepatic steatosis, inflammation, ballooning or fibrosis, and whether it could be used as a serum marker in patients with NAFLD/NASH., Methods: We analysed circulating miR-33a using quantitative PCR in 116 liver transplant recipients who underwent post-transplant protocol liver biopsy. Regression analysis was used to determine association of serum miR-33a with hepatic steatosis, inflammation, ballooning and fibrosis in liver biopsy., Results: Liver graft steatosis and inflammation, but not ballooning or fibrosis, were significantly associated with serum miR-33a, dyslipidemia and insulin resistance markers on univariate analysis. Multivariate analysis showed that steatosis was independently associated with serum miR-33a, ALT, glycaemia and waist circumference, whereas inflammation was independently associated with miR-33a, HbA1 and serum triglyceride levels. Receiver operating characteristic analysis showed that exclusion of serum miR-33a from multivariate analysis resulted in non-significant reduction of prediction model accuracy of liver steatosis or inflammation., Conclusions: Our data indicate that circulating miR-33a is an independent predictor of liver steatosis and inflammation in patients after liver transplantation. Although statistically significant, its contribution to the accuracy of prediction model employing readily available clinical and biochemical variables was limited in our cohort., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
131. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
- Author
-
Senkerikova R, Frankova S, Jirsa M, Kreidlova M, Merta D, Neroldova M, Chmelova K, Spicak J, and Sperl J
- Subjects
- Alleles, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular virology, Case-Control Studies, Cross-Sectional Studies, Female, Genotype, Humans, Liver virology, Liver Cirrhosis virology, Liver Failure virology, Liver Neoplasms genetics, Liver Neoplasms virology, Liver Transplantation methods, Male, Middle Aged, Retrospective Studies, Viral Load methods, Genetic Predisposition to Disease genetics, Hepatitis C, Chronic genetics, Hepatitis C, Chronic virology, Lipase genetics, Liver Cirrhosis genetics, Liver Failure genetics, Membrane Proteins genetics, Polymorphism, Single Nucleotide genetics
- Abstract
Background: PNPLA3 rs738409 minor allele c.444G represents a risk factor for liver steatosis and fibrosis progression also in chronic hepatitis C (HCV). We investigated its impact on the timing of liver transplantation (LT) in patients with genotype 1b HCV cirrhosis., Methods: We genotyped and evaluated 172 LT candidates with liver cirrhosis owing to chronic HCV infection, genotype 1b. One hundred patients needed LT for chronic liver failure (CLF) and 72 for a small hepatocellular carcinoma (HCC) in the cirrhotic liver without CLF. Population controls (n = 647) were selected from the Czech cross-sectional study MONICA., Results: The CLF patients were younger (53.5 ± 7.2 vs. 59.6 ± 6.6, P < 0.001) with more advanced liver disease than HCC patients (Child-Pugh's score 9.1 ± 1.8 vs. 7.1 ± 1.9, P < 0.001, MELD 14.1 ± 3.9 vs. 11.1 ± 3.7, P < 0.001). PNPLA3 G allele increased the risk of LT for CLF in both allelic and recessive models (CG + GG vs. CC: OR, 1.90; 95% CI, 1.017-3.472, P = 0.045 and GG vs. CC + CG: OR, 2.94; 95% CI, 1.032-7.513, P = 0.042). Multivariate analysis identified younger age (P < 0.001) and the G allele (P < 0.05) as risk factors for CLF. The genotype frequencies between the CLF group and MONICA study significantly differed in both, allelic and recessive model (P = 0.004, OR 1.87, 95% CI 1.222-2.875; P < 0.001, OR 3.33, 95% CI 1.824-6.084, respectively). The OR values almost doubled in the recessive model compared with the allelic model suggesting the additive effect of allele G. In contrast, genotype frequencies in the HCC group were similar to the MONICA study in both models. Pretransplant viral load was significantly lower in GG than in CC + CG genotypes (median, IQR; 162,500 (61,550-319,000) IU/ml vs. 570,000 (172,000-1,595,000) IU/ml, P < 0.0009)., Conclusions: Our results suggest that PNPLA3 rs738409 G allele carriage may be associated with a faster progression of HCV cirrhosis to chronic liver failure., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2019
- Full Text
- View/download PDF
132. Accuracy of Colon Capsule Endoscopy for Colorectal Neoplasia Detection in Individuals Referred for a Screening Colonoscopy.
- Author
-
Voska M, Zavoral M, Grega T, Majek O, Martinek J, Tacheci I, Benes M, Vojtechova G, Drastich P, Bures J, Spicak J, Buckova B, Ngo O, and Suchanek S
- Abstract
Backround: Capsule colonoscopy might present an alternative to colonoscopy for colorectal neoplasia screening., Aim: To assess the accuracy of second-generation capsule colonoscopy (CCE2) for colorectal neoplasia detection compared with conventional colonoscopy (CC)., Methods: From 2011-2015, we performed a multicenter, prospective, cross-over study evaluating the use of CCE2 as a possible colorectal cancer (CRC) screening test based on the assessment of the method's characteristics (accuracy) and safety and patient acceptance of the routine. Enrolled participants fulfilled the CRC screening population criteria if they were asymptomatic, were older than 50, and had no personal or familial history of colorectal neoplasia. The primary outcome was accuracy for the detection of polyps ≥ 6 mm. Secondary outcomes were accuracy for all polyps, polyps ≥ 10 mm, adenomas ≥ 10 mm, and cancers, the quality of bowel cleansing, safety, and CCE2 acceptability by the screening population., Results: A total of 236 individuals were examined; 11 patients (5%) were excluded. Therefore, 225 subjects (95%) were considered in the intention-to-screen (ITS) group. A total of 201 patients (89%) completed both examinations successfully (per protocol group). In the ITS group, polyps were diagnosed during CC in 114 subjects (51%); polyps ≥ 6 mm, polyps ≥ 10 mm, and adenomas ≥ 10 mm were diagnosed in 34 (15%), 16 (7%), and 11 (5%) patients, respectively. The sensitivity of CCE2 for polyps ≥ 6 mm, polyps ≥ 10 mm, and adenomas ≥ 10 mm was 79% (95% confidence interval (CI): 62-91%), 88% (95% CI: 62-98%), and 100% (95% CI: 72-100%), respectively., Conclusion: Second-generation capsule colonoscopy is a safe, noninvasive, and sensitive method for colorectal neoplasia detection although CC remains the preferred method for considerable proportion of subjects. CCE2 may therefore be accepted as the primary screening test for colorectal cancer screening., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2019 Michal Voska et al.)
- Published
- 2019
- Full Text
- View/download PDF
133. IL28B rs12979860 T allele protects against CMV disease in liver transplant recipients in the post-prophylaxis and late period.
- Author
-
Chmelova K, Frankova S, Jirsa M, Neroldova M, Sticova E, Merta D, Senkerikova R, Trunecka P, Spicak J, and Sperl J
- Subjects
- Adult, Aged, Alleles, Antiviral Agents therapeutic use, Cohort Studies, Female, Ganciclovir therapeutic use, Genotype, Humans, Incidence, Male, Middle Aged, Polymorphism, Single Nucleotide, Tissue Donors, Transplant Recipients, Young Adult, Cytomegalovirus Infections genetics, Cytomegalovirus Infections prevention & control, Interferons genetics, Liver Transplantation
- Abstract
Background: Cytomegalovirus (CMV) disease represents a serious complication in liver transplant (OLT) recipients. CMV prophylaxis reduces incidence of CMV disease in the early post-transplant period (on-prophylaxis disease, OPD) but may postpone its manifestation after the completion of prophylaxis. Post-prophylaxis disease (PPD) incidence after prophylaxis cessation may be modified by genetic factors., Methods: We analyzed impact of IL28B rs1297986 variants on CMV disease incidence in 743 adult OLT recipients receiving universal prophylaxis., Results: One hundred and forty-four (19.4%) patients had at least one CMV disease episode. One hundred and two of them (70.8%) had at least one OPD and 36 (25%) patients had PPD, six (4.2%) patients had both. The rate of IL28B T allele carriers was lower in PPD group (38.9%) in comparison with OPD group (66.7%, P = 0.005) and group without CMV disease (61.4%, P = 0.009). The impact of IL28B genotype on the risk of CMV OPD was significant neither in the allelic (TT + CT vs CC, P = 0.32) nor in the recessive model (TT vs CT + CC, P = 0.79). Contrarily, in the PPD group, T allele (TT + CT vs CC) had a protective effect, OR 0.4 (95% CI 0.2-0.8, P = 0.008). Further risk factors of PPD were age <55 years and valganciclovir prophylaxis, whereas the risk factors of OPD were age <55 years, cyclosporine A therapy and pre-transplant CMV serostatus (donor +/recipient -)., Conclusions: IL28B rs12979860 T allele carriers had a lower risk of CMV PPD., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
134. Radiofrequency Ablation in Patients with Barrett's Esophagus- related Neoplasia - Long-Term Outcomes in the Czech National Database.
- Author
-
Krajciova J, Janicko M, Falt P, Gregar J, Suchanek S, Ngo O, Kollar M, Urban O, Prochazka V, Zavoral M, Spicak J, and Martinek J
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma in Situ surgery, Catheter Ablation adverse effects, Databases, Factual, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local, Remission Induction, Retrospective Studies, Risk Factors, Treatment Outcome, Young Adult, Barrett Esophagus surgery, Catheter Ablation methods, Esophageal Neoplasms surgery, Precancerous Conditions surgery
- Abstract
Background and Aims: Radiofrequency ablation (RFA) with/without endoscopic resection (ER) is the standard endoscopic treatment modality for Barrett's esophagus (BE) related neoplasia (BORN). The main aim of this study was to assess the long-term outcomes of RFA in patients with BORN., Methods: We retrospectively analyzed the prospectively collected data from the Czech national database. Main outcomes were: complete remission of neoplasia (CR-N), complete remission of intestinal metaplasia (CR-IM), recurrence of both neoplasia and IM, and safety., Results: From a total of 170 patients with BORN treated with RFA, 136 patients were analyzed. They were followed up for a median of 27.5 months. Fifty-six patients (41%) had low-grade intraepithelial neoplasia (LGIN), 46 (34%) had high-grade intraepithelial neoplasia (HGIN) and 34 (25%) had early adenocarcinoma (EAC). RFA was combined with previous ER in 65 patients (48%). CR-IM and CR-N were achieved in 77.9% (95% CI 70.0-84.6%) and 98.5% (95% CI 94.8-99.8%). Among 30 patients without CR-IM, 22 (73%) did not have macroscopic signs of BE. Recurrent neoplasia was detected in 4.5% of patients (6/134) and 15% (16/106) experienced a recurrence of IM at the level of the neo-Z-line. Diagnosis of cancer was an independent risk factor for recurrent IM after RFA (OR 7.0, 95% CI 1.6-30.9, p<0.0005)., Conclusion: RFA is highly effective in achieving remission in patients with BORN. A significant proportion of patients did not achieve CR-IM or had a recurrence of IM despite macroscopically absent BE. Recurrence of neoplasia was infrequent but not negligible, thus, patients after successful RFA still require endoscopic surveillance.
- Published
- 2019
- Full Text
- View/download PDF
135. First genotype-phenotype study reveals HLA-DQβ1 insertion heterogeneity in high-resolution manometry achalasia subtypes.
- Author
-
Vackova Z, Niebisch S, Triantafyllou T, Becker J, Hess T, Kreuser N, Kanoni S, Deloukas P, Schüller V, Heinrichs SK, Thieme R, Nöthen MM, Knapp M, Spicak J, Gockel I, Schumacher J, Theodorou D, and Martinek J
- Subjects
- Alleles, Cross-Sectional Studies, Czech Republic, Esophageal Achalasia epidemiology, Geography, Medical, Germany, Greece, HLA-DQ beta-Chains immunology, Humans, Polymorphism, Single Nucleotide, Population Surveillance, Prevalence, Esophageal Achalasia diagnosis, Esophageal Achalasia etiology, Genetic Heterogeneity, Genotype, HLA-DQ beta-Chains genetics, Manometry, Phenotype
- Abstract
Background: Achalasia is a primary oesophageal motility disorder. Although aetiology remains mainly unknown, a genetic risk variant, rs28688207 in HLA-DQB1, showed strong achalasia association suggesting involvement of immune-mediated processes in the pathogenesis. High-resolution manometry recognises three types of achalasia. The aim of our study was to perform the first genotype-phenotype analysis investigating the frequency of rs28688207 across the high-resolution manometry subtypes., Methods: This was a cross-sectional retrospective study. Achalasia patients from tertiary centres in the Czech Republic ( n = 163), Germany ( n = 114), Greece ( n = 70) and controls were enrolled. All subjects were genotyped for the rs28688207 insertion. The Kruskal-Wallis test was used for the genotype-phenotype analysis., Results: A total of 347 achalasia patients (type I - 89, II - 210, III - 48) were included. The overall frequency of the rs28688207 was 10.3%. The distribution of the insertion was significantly different across the high-resolution manometry subtypes ( p = 0.038), being most prevalent in type I (14.6%), followed by type II (9.5%) and III (6.3%)., Conclusion: The frequency of the HLA-DQB1 insertion differs among high-resolution manometry achalasia subtypes. The insertion is most prevalent in type I, suggesting that immune-mediated mechanisms triggered by the insertion may play a more prominent role in the pathogenesis of this subtype.
- Published
- 2019
- Full Text
- View/download PDF
136. Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing.
- Author
-
Heczkova M, Machackova E, Macinga P, Gallmeier E, Cahova M, Spicak J, Jirsa M, Foretova L, and Hucl T
- Subjects
- Adult, Aged, Cell Line, Tumor, Czech Republic, DNA Mutational Analysis methods, Exons genetics, Feasibility Studies, Female, Humans, Male, Markov Chains, Medical History Taking, Middle Aged, Mutation, Neoplasms diagnosis, Risk Assessment methods, BRCA2 Protein genetics, Genetic Predisposition to Disease, Genetic Testing methods, Models, Biological, Neoplasms genetics
- Abstract
Heterozygous germline BRCA2 mutations predispose to breast, ovarian, pancreatic and other types of cancer. The presence of a pathogenic mutation in patients or their family members warrants close surveillance or prophylactic surgery. Besides clearly pathogenic mutations, variants leading only to a single amino acid substitution are often identified. The influence of such variants on cancer risk is often unknown, making their presence a major clinical problem. When genetic methods are insufficient to classify these variants, functional assays with various cellular models are performed. We developed and applied a new syngeneic model of human cancer cells to test all variants of unknown significance in exon 18 identified by genetic testing of high-risk cancer patients in the Czech Republic, via introduction of constructs containing each of these variants into the wild-type allele of BRCA2-heterozygous DLD1 cells (BRCA2
wt/Δex11 ). We found unaffected DNA repair function of BRCA2 in cell lines BRCA27997G>C/Δex11 , BRCA28111C>T/Δex11 , BRCA28149G>T/Δex11 , BRCA28182G>A/Δex11 , and BRCA28182G>T/Δex11 , whereas the cell line BRCA28168A>G/Δex11 and the nonsense mutation carrying line BRCA28305G>T/ Δex11 did affect protein function. Targeting the BRCA2 wild-type allele with a construct carrying the variant c.7988A> G resulted in incorporation exclusively into the already defective allele in all viable clones, strongly suggesting a detrimental phenotype. Our model thus offers a valuable tool for the functional evaluation of unclassified variants in the BRCA2 gene and provides a stable and distributable cellular resource for further research.- Published
- 2019
- Full Text
- View/download PDF
137. Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer.
- Author
-
Kral J, Korenkova V, Novosadova V, Langerova L, Schneiderova M, Liska V, Levy M, Veskrnova V, Spicak J, Opattova A, Jiraskova K, Vymetalkova V, Vodicka P, and Slyskova J
- Subjects
- Biomarkers, Tumor genetics, Cell Line, Tumor, Cell Proliferation genetics, Gene Expression Profiling, Gene Expression Regulation, Neoplastic genetics, Humans, Rectal Neoplasms mortality, Treatment Outcome, Antineoplastic Agents therapeutic use, MicroRNAs genetics, Rectal Neoplasms drug therapy, Rectal Neoplasms genetics
- Abstract
MicroRNA (miRNA) profiling represents a promising source of cancer-related biomarkers. miRNA signatures are specific for each cancer type and subgroups of patients with diverse treatment sensitivity. Yet this miRNA potential has not been satisfactorily explored in rectal cancer (RC). The aim of the study was to identify the specific miRNA signature with clinical and therapeutic relevance for RC. Expressions of 2555 miRNA were examined in 20 pairs of rectal tumors and matched non-malignant tissues by 3D-Gene Toray microarray. Candidate miRNAs were validated in an independent cohort of 100 paired rectal tissues and in whole plasma and exosomes of 100 RC patients. To study the association of miRNA profile with therapeutic outcomes, plasma samples were taken repeatedly over a time period of 1 year reflecting thus patients' treatment responses. Finally, the most prominent miRNAs were investigated in vitro for their involvement in cell growth. We identified RC-specific miRNA signature that distinguishes responders from non-responders to adjuvant chemotherapy. A predominant part of identified miRNAs was represented by the members of miR-17/92 cluster. Upregulation of miRNA-17, -18a, -18b, -19a, -19b, -20a, -20b and -106a in tumor was associated with higher risk of tumor relapse and their overexpression in RC cell lines stimulated cellular proliferation. Examination of these miRNAs in plasma exosomes showed that their levels differed between RC patients and healthy controls and correlated with patient's treatment response. miRNAs from miR-17/92 cluster represent a non-invasive biomarker to predict posttreatment prognosis in RC patients.
- Published
- 2018
- Full Text
- View/download PDF
138. Peroral endoscopic myotomy and peroral endoscopic pyloromyotomy as a single procedure for concomitant achalasia and gastroparesis.
- Author
-
Erhartova D, Vackova Z, Hustak R, Spicak J, and Martinek J
- Subjects
- Aged, Endoscopy, Gastrointestinal, Esophageal Achalasia complications, Female, Gastroparesis complications, Humans, Esophageal Achalasia surgery, Gastroparesis surgery, Heller Myotomy methods, Pyloromyotomy methods
- Abstract
Competing Interests: None, (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2018
- Full Text
- View/download PDF
139. Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease.
- Author
-
Bajer L, Slavcev A, Macinga P, Sticova E, Brezina J, Roder M, Janousek R, Trunecka P, Spicak J, and Drastich P
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Cholangiopancreatography, Endoscopic Retrograde, Cholangitis, Sclerosing diagnostic imaging, Cholangitis, Sclerosing surgery, Colon diagnostic imaging, Colon pathology, Colonoscopy, Female, Follow-Up Studies, Humans, Inflammatory Bowel Diseases diagnostic imaging, Inflammatory Bowel Diseases pathology, Intestinal Mucosa diagnostic imaging, Intestinal Mucosa pathology, Liver diagnostic imaging, Liver pathology, Magnetic Resonance Imaging, Male, Middle Aged, Recurrence, Retrospective Studies, Risk Assessment methods, Risk Factors, Tissue Donors statistics & numerical data, Young Adult, Cholangitis, Sclerosing pathology, Inflammatory Bowel Diseases epidemiology, Liver Transplantation
- Abstract
Aim: To evaluate risk factors for primary sclerosing cholangitis (PSC) recurrence (rPSC) after orthotopic liver transplantation (OLT) in patients with well-preserved colons., Methods: We retrospectively evaluated the medical records of all patients transplanted for PSC in our center between July 1994 and May 2015 and selected 47 with follow-up of at least 60 mo for further analysis based on strict inclusion and exclusion criteria. rPSC was confirmed by magnetic resonance or endoscopic retrograde cholangiopancreatography and liver biopsy. All patients were evaluated by protocolary pre-OLT colonoscopy with randomized mucosal biopsies. Colonoscopy was repeated annually after OLT. Both organ donors and recipients were human leukocyte antigen (HLA) typed by serological and/or DNA methods. All input data were thoroughly analyzed employing relevant statistical methods., Results: Altogether, 31 men and 16 women with a median (range) age of 36 (15-68) years at the time of OLT and a median follow-up of 122 (60-249) mo were included. rPSC was confirmed in 21/47 (44.7%) of patients, a median 63 (12-180) mo after transplantation. De novo colitis [rPSC in 11/12, P ≤ 0.05, hazard ratio (HR): 4.02, 95% confidence interval (CI): 1.58-10.98] and history of acute cellular rejection (rPSC in 14/25, P ≤ 0.05; HR: 2.66, 95%CI: 1.03-7.86) showed strong positive associations with rPSC. According to the univariate analysis, overlapping features of autoimmune hepatitis (rPSC in 5/5, P ≤ 0.05) and HLA-DRB1*07 in the donor (rPSC in 10/15, P ≤ 0.05) represent other potential risk factors for rPSC, while the HLA-DRB1*04 (rPSC in 0/6, P ≤ 0.05), HLA-DQB1*03 (rPSC in 1/11, P ≤ 0.05), and HLA-DQB1*07 (rPSC in 0/7, P ≤ 0.05) recipient alleles may have protective roles., Conclusion: De novo colitis and acute cellular rejection are clinical conditions significantly predisposed towards recurrence of PSC after liver transplantation., Competing Interests: Conflict-of-interest statement: All authors declare that there are no competing interests regarding the publication of this paper.
- Published
- 2018
- Full Text
- View/download PDF
140. Role of confocal laser endomicroscopy in patients with early esophageal neoplasia.
- Author
-
Kollar M, Spicak J, Honsova E, Krajciova J, Vackova Z, and Martinek J
- Subjects
- Humans, Microscopy, Confocal instrumentation, Microscopy, Confocal methods, Neoplasm Staging, Esophageal Neoplasms pathology, Esophagoscopy
- Abstract
Probe-based confocal laser endomicroscopy (pCLE) enables real-time histopathological assessment during endoscopic procedures to evaluate epithelial and subepithelial structures with a 1000x magnification. It may be used in various localizations not only in the digestive tract, but its role in clinical practice is still a matter of discussion. The main advantages of pCLE compared to standard biopsies may be: 1) real-time diagnosis; 2) which may be done by the endoscopist; and 3) a larger evaluated area compared to standard biopsies. In theory, pCLE has the potential to eliminate the need for biopsy. However, pCLE cannot replace standard biopsies at this time, among others, standard forceps biopsies are presently more cost-effective. pCLE may be used to enhance the diagnostic arsenal and improve mucosal visualization and evaluation in patients with Barrett's esophagus (BE), with visible esophageal lesions and in patients undergoing surveillance endoscopy after endoscopic treatment of BE related neoplasia. pCLE requires sufficient training and use of validated classifications systems. At present, the majority of endoscopic centers do not use pCLE routinely and no guidelines recommend its routine use for patients with different esophageal diseases, although pCLE is (in selected indications) reimbursed in some countries. This article describes the principle and performance of pCLE and reviews its use in patients with BE and early esophageal neoplasia.
- Published
- 2018
- Full Text
- View/download PDF
141. Radiofrequency ablation for Barrett's esophagus-related neoplasia.
- Author
-
Krajciova J, Vackova Z, Spicak J, and Martinek J
- Subjects
- Barrett Esophagus complications, Esophageal Neoplasms etiology, Humans, Esophageal Neoplasms surgery, Esophagectomy methods, Radiofrequency Ablation
- Abstract
Barrett's esophagus (BE) is a premalignant condition associated with increased risk of developing esophageal adenocarcinoma. In the past, BE patients with high-grade intraepithelial neoplasia (IEN) or early adenocarcinoma (EAC) were indicated for esophagectomy. With the recent advance in endoscopy, endoscopic techniques have surpassed esophagectomy in the treatment of Barrett's esophagus-related neoplasia and minimized the treatment-related morbidity. Patients with IEN are candidates for endoscopic treatment - endoscopic mucosal resection (ER) of visible lesions and/or ablation therapy of flat Barrett's mucosa. ER combined with radiofrequency ablation (RFA) is now considered as a gold standard for treatment of patients with early Barrett's cancer. RFA is currently the most effective method of ablation used in the treatment of low-grade intraepithelial neoplasia/high-grade intraepithelial neoplasia without visible lesions and for ablation of residual Barrett's mucosa following ER/ESD of EAC or HGIN aiming to achieve complete eradication of Barrett's surface and thus, decreasing the risk of recurrent dysplasia or cancer. The rates of complete remission of neoplasia and metaplasia after completion of endoscopic treatment are 81-92.6% and 75-88.2%, respectively. The aim of this article is to review the principles, techniques, indications, efficacy and safety of this ablative method and surveillance of patients after successful treatment with RFA.
- Published
- 2018
- Full Text
- View/download PDF
142. Erratum to: Per-oral endoscopic myotomy (POEM): mid-term efficacy and safety.
- Author
-
Martinek J, Svecova H, Vackova Z, Dolezel R, Ngo O, Krajciova J, Kieslichova E, Janousek R, Pazdro A, Harustiak T, Zdrhova L, Loudova P, Stirand P, and Spicak J
- Abstract
The Given Names and Family Names were all inadvertently inverted. The correct order is: Jan Martinek, Hana Svecova, Zuzana Vackova, Radek Dolezel, Ondrej Ngo, Jana Krajciova, Eva Kieslichova, Radim Janousek, Alexander Pazdro, Tomas Harustiak, Lucie Zdrhova, Pavla Loudova, Petr Stirand, Julius Spicak. The original article was corrected.
- Published
- 2018
- Full Text
- View/download PDF
143. Per-oral endoscopic myotomy (POEM): mid-term efficacy and safety.
- Author
-
Martinek J, Svecova H, Vackova Z, Dolezel R, Ngo O, Krajciova J, Kieslichova E, Janousek R, Pazdro A, Harustiak T, Zdrhova L, Loudova P, Stirand P, and Spicak J
- Subjects
- Adolescent, Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Young Adult, Esophageal Achalasia surgery, Heller Myotomy methods, Natural Orifice Endoscopic Surgery methods
- Abstract
Background and Aims: Per-oral endoscopic myotomy (POEM) is becoming a standard treatment for achalasia. Long-term efficacy and the rate of post-POEM reflux should be further investigated. The main aim of this study was to analyze safety and mid-term (12 and 24 months) clinical outcomes of POEM., Methods: Data on single tertiary center procedures were collected prospectively. The primary outcome was treatment success defined as an Eckardt score < 3 at 12 and 24 months. A total of 155 consecutive patients with achalasia underwent POEM; 133 patients were included into the analysis (22 patients will be analyzed separately as part of a multicenter randomized clinical trial)., Results: POEM was successfully completed in 132 (99.2%) patients, and the mean length of the procedure was 69.8 min (range 31-136). One patient underwent a drainage for pleural effusion; no other serious adverse events occurred. Treatment success at 3, 12, and 24 months was observed in 95.5% (CI 89.6-98.1), 93.4% (86.5-96.8), and 84.0% (71.4-91.4) of patients, respectively. A total of 11 patients (8.3%) reported initial treatment failure (n = 5) or later recurrence (n = 6). The majority of relapses occurred in patients with achalasia type I (16.7 vs. 1.1% achalasia type II vs. 0% achalasia type III; p<0.05). At 12 months, post-POEM reflux symptoms were present in 29.7% of patients. At 3 months, mild reflux esophagitis was diagnosed in 37.6% of patients, and pathological gastroesophageal reflux was detected in 41.5% of patients. A total of 37.8% of patients had been treated with a proton pump inhibitor., Conclusion: POEM resulted in greater than 90% treatment success at 12 months which tends to decrease to 84% after 2 years. More than one-third of the patients had mild reflux symptoms and/or mild esophagitis.
- Published
- 2018
- Full Text
- View/download PDF
144. Gentamicin submucosal lavage during peroral endoscopic myotomy (POEM): a retrospective analysis.
- Author
-
Bayer J, Vackova Z, Svecova H, Stirand P, Spicak J, and Martinek J
- Subjects
- Adult, Ceftriaxone administration & dosage, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Antibiotic Prophylaxis, Endoscopy, Gastrointestinal methods, Esophageal Achalasia surgery, Gentamicins administration & dosage, Myotomy methods, Natural Orifice Endoscopic Surgery methods, Therapeutic Irrigation methods
- Abstract
Background and Aims: Peroral endoscopic myotomy (POEM) is an evolving therapeutic modality for achalasia. According to the original Inoue's technique, a submucosal lavage with gentamicin has been practiced due to the fear of infection. This single-tertiary center study was intended to assess the clinical significance of the topical antibiotic lavage during POEM., Methods: A retrospective analysis of prospectively collected data was conducted. The outcomes of patients who received the gentamicin lavage (group A) during POEM were compared to those who did not (group B). The main outcome variables were infectious adverse events, post-POEM fever, and markers of systemic inflammatory response. One day before and after POEM, all patients received systemic antibiotic prophylaxis with ceftriaxone., Results: Of 124 consecutive patients having undergone POEM, 60 patients received a lavage with 80 mg of gentamicin into the submucosal tunnel before starting the myotomy, while 64 patients did not. The overall treatment success at 3 months did not differ between the two groups (group A 94.7 vs. 97.5% group B). We did not experience any significant infectious adverse events in either group. CRP and WBC levels were lower in patients with lavage versus those without [CRP: median 52.7 (IQR 34.9) vs. 69.5 (54.1); p = 0.01; WBCs: median 10.9 (IQR 3.3) vs. 12.6 (3.9); p < 0.01]. Post-procedural fever was present in 10% of patients in either group., Conclusions: During POEM, the submucosal lavage with gentamicin prior to the myotomy does not play a role in the prevention of clinically significant infectious adverse events, although the systemic inflammatory response may be decreased.
- Published
- 2018
- Full Text
- View/download PDF
145. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis.
- Author
-
Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, and Drastich P
- Subjects
- Adult, Aged, Bacteria genetics, Cholangitis, Sclerosing microbiology, Colitis, Ulcerative microbiology, Dysbiosis etiology, Feces microbiology, Female, Healthy Volunteers, Humans, Intestinal Mucosa microbiology, Male, Middle Aged, RNA, Ribosomal, 16S isolation & purification, Sequence Analysis, RNA, Bacteria isolation & purification, Cholangitis, Sclerosing complications, Colitis, Ulcerative complications, Colon microbiology, Dysbiosis microbiology, Gastrointestinal Microbiome
- Abstract
Aim: To characterize the gut bacterial microbiota of patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC)., Methods: Stool samples were collected and relevant clinical data obtained from 106 study participants, 43 PSC patients with ( n = 32) or without ( n = 11) concomitant inflammatory bowel disease, 32 UC patients, and 31 healthy controls. The V3 and V4 regions of the 16S ribosomal RNA gene were sequenced on Illumina MiSeq platform to cover low taxonomic levels. Data were further processed in QIIME employing MaAsLin and LEfSe tools for analysis of the output data., Results: Microbial profiles in both PSC and UC were characterized by low bacterial diversity and significant change in global microbial composition. Rothia , Enterococcus , Streptococcus , Veillonella , and three other genera were markedly overrepresented in PSC regardless of concomitant inflammatory bowel disease (IBD). Rothia , Veillonella and Streptococcus were tracked to the species level to identify Rothia mucilaginosa , Streptococcus infantus , S. alactolyticus , and S. equi along with Veillonella parvula and V. dispar . PSC was further characterized by decreased abundance of Adlercreutzia equolifaciens and Prevotella copri . Decrease in genus Phascolarctobacterium was linked to presence of colonic inflammation regardless of IBD phenotype. Akkermansia muciniphila , Butyricicoccus pullicaecorum and Clostridium colinum were decreased in UC along with genus Roseburia . Low levels of serum albumin were significantly correlated with enrichment of order Actinomycetales., Conclusion: PSC is associated with specific gut microbes independently of concomitant IBD and several bacterial taxa clearly distinguish IBD phenotypes (PSC-IBD and UC)., Competing Interests: Conflict-of-interest statement: The authors declare that there are no competing interests regarding the publication of this paper.
- Published
- 2017
- Full Text
- View/download PDF
146. Simultaneous occurrence of autoimmune pancreatitis and pancreatic cancer in patients resected for focal pancreatic mass.
- Author
-
Macinga P, Pulkertova A, Bajer L, Maluskova J, Oliverius M, Smejkal M, Heczkova M, Spicak J, and Hucl T
- Subjects
- Adenocarcinoma complications, Adult, Aged, Autoimmune Diseases complications, Female, Humans, Immunoglobulin G blood, Male, Middle Aged, Pancreas pathology, Pancreatectomy, Pancreatic Neoplasms complications, Pancreatitis complications, Retrospective Studies, Adenocarcinoma diagnosis, Adenocarcinoma surgery, Autoimmune Diseases diagnosis, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms surgery, Pancreatitis diagnosis
- Abstract
Aim: To assess the occurrence of autoimmune pancreatitis (AIP) in pancreatic resections performed for focal pancreatic enlargement., Methods: We performed a retrospective analysis of medical records of all patients who underwent pancreatic resection for a focal pancreatic enlargement at our tertiary center from January 2000 to July 2013. The indication for surgery was suspicion of a tumor based on clinical presentation, imaging findings and laboratory evaluations. The diagnosis of AIP was based on histology findings. An experienced pathologist specialized in pancreatic disease reviewed all the cases and confirmed the diagnosis in pancreatic resection specimens suggestive of AIP. The histological diagnosis of AIP was set according to the international consensus diagnostic criteria., Results: Two hundred ninety-five pancreatic resections were performed in 201 men and 94 women. AIP was diagnosed in 15 patients (5.1%, 12 men and 3 women) based on histology of the resected specimen. Six of them had AIP type 1, nine were diagnosed with AIP type 2. Pancreatic adenocarcinoma (PC) was also present in six patients with AIP (40%), all six were men. Patients with AIP + PC were significantly older (60.5 vs 49 years of age, P = 0.045), more likely to have been recently diagnosed with diabetes (67% vs 11%, P = 0.09), and had experienced greater weight loss (15.5 kg vs 8.5 kg, P = 0.03) than AIP patients without PC. AIP was not diagnosed in any patients prior to surgery; however, the diagnostic algorithm was not fully completed in every case., Conclusion: The possible co-occurrence of PC and AIP suggests that preoperative diagnosis of AIP does not rule out simultaneous presence of PC., Competing Interests: Conflict-of-interest statement: We have no financial relationship to disclose.
- Published
- 2017
- Full Text
- View/download PDF
147. Complications of percutaneous endoscopic gastrostomy.
- Author
-
Hucl T and Spicak J
- Subjects
- Enteral Nutrition, Humans, Intubation, Gastrointestinal methods, Postoperative Complications prevention & control, Gastroscopy adverse effects, Gastrostomy adverse effects, Gastrostomy methods, Intubation, Gastrointestinal adverse effects, Postoperative Complications etiology
- Abstract
Percutaneous endoscopic gastrostomy (PEG) has become the method of choice for mid-to long-term enteral feeding. The majority of complications that occur are minor, but the rare major complications may be life threatening. Some complications occur soon after tube placement, others develop later, when the gastrostomy tract has matured. Older patients with comorbidities and infections appear to be at a greater risk of developing complications. Apart from being aware of indications and contraindications, proper technique of PEG placement, including correct positioning of the external fixation device, and daily tube care are important preventive measures. Adequate management of anticoagulation and antithrombotic agents is important to prevent bleeding, and administration of broad spectrum antibiotics prior to the procedure helps prevent infectious complications. Early recognition of complications enables prompt diagnosis and effective therapy., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
148. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes.
- Author
-
Hejlova I, Honsova E, Sticova E, Lanska V, Hucl T, Spicak J, Jirsa M, and Trunecka P
- Subjects
- Adult, Alcohol Drinking, Alkaline Phosphatase blood, Biopsy, Diabetes Mellitus, Type 2 blood, Disease Progression, Female, Humans, Liver Cirrhosis blood, Male, Middle Aged, Multivariate Analysis, Mycophenolic Acid administration & dosage, Prevalence, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Triglycerides blood, Liver Transplantation adverse effects, Non-alcoholic Fatty Liver Disease epidemiology, Non-alcoholic Fatty Liver Disease etiology
- Abstract
Steatosis occurs frequently after liver transplantation (LT). We aimed to determine the prevalence of steatosis in adult LT recipients, to determine the effects of significant (>33%; grades 2-3) steatosis on patient survival, and to identify risk factors for the development of significant steatosis and its effect on fibrosis progression. We retrospectively examined 2360 posttransplant biopsies of 548 LT recipients. Survival was compared between patients with significant steatosis and those with grades 0-1 steatosis. Patients with significant steatosis were compared to controls without steatosis (grade 0) for clinical and laboratory factors and fibrosis progression. Steatosis was found in 309 (56.4%) patients, including 93 (17.0%) patients with significant steatosis. Steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) was diagnosed in 57 (10.4%) patients. The prevalence of steatosis increased from 30.3% at 1 year to 47.6% at 10 years after LT (P < 0.001). Survival times did not differ between groups (P = 0.29). On multivariate analysis of pretransplant factors and initial immunosuppression (IS), alcohol-induced cirrhosis (P < 0.001) and high body mass index (BMI; P = 0.002) were associated with the development of significant steatosis, whereas increased levels of alkaline phosphatase (P = 0.01) and mycophenolate mofetil given initially (P = 0.009) appeared to protect against significant steatosis. On multivariate analysis of posttransplant factors, high BMI (P < 0.001), serum triglycerides (P < 0.001), alcohol consumption (P = 0.005), and type 2 diabetes mellitus (P = 0.048) were associated with significant steatosis, whereas high creatinine (P = 0.02) appeared to protect against significant steatosis. Significant steatosis was not associated with a higher fibrosis stage (P = 0.62). Posttransplant steatosis affects 56.4% of LT recipients, and the prevalence increases with time after LT. Recipient factors and types of IS affect the risk for significant steatosis, which is not associated with a higher fibrosis stage or worse patient survival. Liver Transplantation 22 644-655 2016 AASLD., (© 2015 American Association for the Study of Liver Diseases.)
- Published
- 2016
- Full Text
- View/download PDF
149. Comparison of Inflammatory Response to Transgastric and Transcolonic NOTES.
- Author
-
Hucl T, Benes M, Kocik M, Splichalova A, Maluskova J, Krak M, Lanska V, Heczkova M, Kieslichova E, Oliverius M, and Spicak J
- Abstract
Aims. The aim of our study was to determine the physiologic impact of NOTES and to compare the transgastric and transcolonic approaches. Methods. Thirty pigs were randomized to transgastric, transcolonic, or laparoscopic peritoneoscopy. Blood was drawn and analyzed for C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin- (IL-) 1β, IL-6, WBCs, and platelets. Results. Endoscopic closure with an OTSC was successful in all 20 animals. The postoperative course was uneventful in all animals. CRP values rose on day 1 in all animals and slowly declined to baseline levels on day 14 with no differences between the groups (P > 0.05, NS). The levels of TNF-α were significantly increased in the transcolonic group (P < 0.01); however this difference was already present prior to the procedure and remained unchanged. No differences were observed in IL1-β and IL-6 values. There was a temporary rise of WBC on day 1 and of platelets on day 7 in all groups (P > 0.05, NS). Conclusions. Transgastric, transcolonic, and laparoscopic peritoneoscopy resulted in similar changes in systemic inflammatory markers. Our findings do not support the assumption that NOTES is less invasive than laparoscopy.
- Published
- 2016
- Full Text
- View/download PDF
150. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
- Author
-
Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, and Jirsa M
- Subjects
- Adolescent, Adult, Aged, Chi-Square Distribution, Drug Therapy, Combination, Female, Genotype, Hepacivirus genetics, Hepatitis C, Chronic complications, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic genetics, Humans, Interferons, Interleukins genetics, Kidney Failure, Chronic complications, Kidney Failure, Chronic diagnosis, Logistic Models, Male, Middle Aged, Multivariate Analysis, Phenotype, Recombinant Proteins therapeutic use, Retrospective Studies, Risk Factors, Treatment Outcome, Young Adult, Antiviral Agents therapeutic use, Hepacivirus drug effects, Hepatitis C, Chronic drug therapy, Interferon-alpha therapeutic use, Kidney Failure, Chronic therapy, Polyethylene Glycols therapeutic use, Renal Dialysis, Ribavirin therapeutic use, Viral Load
- Abstract
Aim: To identify predictors of sustained virological response in hemodialysed patients treated by PEGinterferon α for chronic hepatitis C, genotype 1., Methods: The sustained virological response (SVR) rate, IL28B genotype, IFNL4 genotype, initial viral load (IVL) and other pretreatment variables in 39 end-stage renal disease patients (ESRD) on maintenance haemodialysis (HD) infected with hepatitis C virus (HCV), genotype 1b, were compared with a control group of 109 patients with normal kidney function treated within the same period. All the patients were treatment naïve and had well compensated liver disease. The ESRD patients received 135 μg of PEGylated interferon α-2a (PegIFN-α) weekly and a reduced dose of ribavirin (RBV) was administered to 23/39 patients with an initial haemoglobin level > 10 g/dL. Control group patients were given standard doses of PegIFN-α and RBV. SVR was assessed as HCV RNA negativity 24 wk post-treatment. A t-test or ANOVA were used for comparisons of the means and a χ(2) test compared the frequencies. Logistic regression was used to determine significant predictors of SVR. Cutoff values for continuous variables were obtained from Receiver Operating Characteristic analysis., Results: The distribution of IL28B rs12979860 CC, CT and TT genotypes in the ESRD group was 28.2%, 64.1% and 7.7%, respectively, and 19.3%, 62.4% and 18.3% in the controls. The IFNL4 genotype was in almost absolute linkage disequlibrium with IL28B. The proportion of patients with a low IVL (< 600000 IU/mL) was significantly higher in the ESRD group than in the controls (28/39, 71.8% vs 51/109, 46.8%, P = 0.009), as was the proportion of patients with low IVL in IL28B CC carriers compared with non-CC carriers in the ESRD group (10/11, 90.9% vs 18/28, 64.3%, P = 0.0035). This difference was not found in the controls (7/22, 31.8% vs 44/87, 50.6%, P = 0.9). The overall SVR rate was 64.1% (25/39) in the ESRD group and 50.5% (55/109) in the control group (P = 0.19). 11/11 (100%) and 19/22 (86.4%) IL28B CC patients achieved SVR in the ESRD and control groups, respectively. A statistically significant association between SVR and IL28B and IFNL4 variants was found in both groups. The ESRD patients who achieved SVR showed the lowest IVL [median 21000, interquartile range (IQR): 6000-23000 IU/mL], compared with ESRD individuals without SVR (1680000, IQR: 481000-6880000, P = 0.001), controls with SVR (387000, IQR: 111000-1253000) and controls without SVR (905000, IQR: 451000-3020000). In ESRD, an IVL < 600000 IU/mL was strongly associated with SVR: 24/28 (85.7%) patients who achieved SVR had viraemia below this threshold., Conclusion: Haemodialysis decreases the viral load, especially in IL28B CC genotype carriers. A low IVL was the strongest predictor of SVR in ESRD patients identified in multivariate analysis.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.